Hemoglobin Glycation Index valuable Biomarker for Frailty and Mortality in Hypertension: Study

Written By :  Dr Riya Dave
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-11-18 03:30 GMT   |   Update On 2025-11-18 03:30 GMT
Advertisement

According to a new study Hemoglobin Glycation Index (HGI) is a valuable biomarker in hypertensive patients: higher HGI levels are linked to increased frailty risk, and its U-shaped association with all-cause mortality underscores its importance for risk stratification. The study was published in BMC Diabetology & Metabolic Syndrome by Zebin Lin and colleagues.

In the study, 1773 hypertensive participants from the CHARLS database were analyzed. HGI was calculated by the following formula: HGI = measured HbA1c – predicted HbA1c. Frailty and mortality associations were examined by multivariable logistic regression, Cox proportional hazards regression, mediation analysis, and threshold effect detection. The investigators specifically assessed whether diabetes acted as a mediator and explored possible inflection points in the HGI–mortality curve for non-linear patterns.

Advertisement

Results

  • HGI was independently associated with frailty, with an adjusted OR of 1.28 (95% CI: 1.03–1.60).

  • Mediation analysis showed that diabetes accounted for 27.8% of the link between increasing HGI and the risk of frailty, supporting the hypothesis that hyperglycemia is a major factor in the functional decline of hypertensive patients.

  • The researchers found a U-shaped relationship for mortality, with an inflection point at HGI = –0.15.

  • Among the overall hypertensive sample, in those with HGI ≥ –0.15, the association of HGI with mortality was not statistically significant (adjusted HR 1.17; 95% CI: 0.92–1.50).

  • Among frail patients in this same HGI range, however, every 1-unit increase in HGI was associated with a 60% increased risk of mortality (HR 1.60; 95% CI: 1.11–2.32).

  • When HGI was less than –0.15, higher HGI values were related to lower mortality in the general hypertensive population, with an adjusted HR of 0.68; 95% CI: 0.49–0.95.

  • A somewhat similar protective trend seems to have appeared in the frailty subgroup, where the adjusted HR was 0.36; 95% CI: 0.13–0.97.

This study showed that HGI is a meaningful biomarker of frailty and mortality in hypertensive patients. These findings indicate that HGI can be used to guide risk stratification and enhance clinical decision-making in managing hypertension.

Reference:

Lin, Z., Dong, Y., Di, X. et al. Association of hemoglobin glycation index with frailty and all-cause mortality in hypertensive patients. Diabetol Metab Syndr 17, 417 (2025). https://doi.org/10.1186/s13098-025-01994-0


Tags:    
Article Source : BMC Diabetology & Metabolic Syndrome

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News